3 articles tagged with #amgen. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Amgen CEO Bob Bradway made early bets on AI in biotech, positioning the company to leverage artificial intelligence for drug discovery and development. The strategy is now generating measurable returns while forcing the organization to navigate tensions between AI-driven automation and the need for specialized scientific expertise.
OpenAI has launched GPT-Rosalind, an AI model designed to accelerate pharmaceutical drug discovery, partnering with major life sciences companies including Amgen, Moderna, and Thermo Fisher. The model represents a significant application of advanced AI technology beyond traditional software domains, with potential to compress drug development timelines and reduce research costs.
The article discusses how pharmaceutical company Amgen utilizes GPT-5 technology in their operations. However, the article body provides insufficient detail to analyze the specific applications or implications of this AI integration.
